Clinical Trial Detail

NCT ID NCT03010176
Title Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Merck Sharp & Dohme Corp.
Indications

lymphoma

Advanced Solid Tumor

Therapies

MK-1454 + Pembrolizumab

MK-1454

Age Groups: adult senior

No variant requirements are available.